Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts
Vical Incorporated has announced that the company addressed an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company’s DNA vaccine technology and Vaxfectin(R) adjuvant. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other cell culture methods.
For the full story, Click Here





A new study published in The Lancet depicts that GlaxoSmithKline’s human papillomavirus (HPV) vaccine is highly effective at preventing precancerous cervical lesions that can lead to cervical cancer. The researchers said that the HPV-16/18 AS04-adjuvanted vaccine was as much as 98% effective against HPV-16/18, and between 37% and 54% effective against 12 other cancer-causing HPV types.